Registration

For Groups larger than 10 delegates, please email chantell@soafrica.com

Early Bird
Until 15 January 2026 (USD)
From 16 January 2026
Until 26 March 2026 (USD)
International Delegates – Member AfSBT 400 440
International Delegates – Non-Member AfSBT 500 550
Namibia Delegates –   Member AfSBT 340 370
Namibia Delegates –   Non-Member AfSBT 360 400
Student 170 185
“Enhancing the Blood and Transfusion Ecosystems” Business Partners Meeting and Dinner (Gala Dinner) 50 50

Student registration: must be accompanied by a copy of the student registration card for 2025/2026

Full registration fee includes

  • Attendance to the scientific sessions
  • Congress bag and materials
  • Attendance to the “Connect With The Industry”: Cocktail Reception and Opening of the Trade Exhibition
  • Lunch and tea/coffee breaks

What is not included in the Registration Fee?

  • Attendance at the “Enhancing the Blood and Transfusion Ecosystems” Business Partners Meeting and Dinner (Gala Dinner)
  • Special catering requirements
  • Any other items not mentioned above

Visa Invitation Letter

All fully paid registered delegates will receive a link in their registration confirmation letter. Please follow the link to download the visa letter.

Registration Terms and Conditions

 

  • All participants are required to complete their registrations and applications online. By submitting the Congress registration form, the delegate acknowledges their acceptance of the Terms and Conditions outlined herein. Please note that the registration is considered confirmed only upon receipt of the full registration fee by the Congress Secretariat.
  • Access to attendance at the AfSBT Congress 2026 will only be confirmed on receipt of payment. Payment is due prior to the start of the congress.
  • All early-bird fees must be paid by the closing date of the early-bird time period (23:59 SAST 15 January 2026). Nonpayment will result in the delegate registration being converted to the Regular Registration and will be liable for the Regular Registration fees.
  • An invoice with the congress bank details will be emailed to you within 72 hours of your completed registration.
  • Receipts will only be issued once proof of payment has been received and identified in the congress bank account. Proof of payment is to be emailed to Chantell Joyce – chantell@soafrica.com.
  • Please ensure that all payments make clear reference to the delegate being paid for, with their unique Registration ID number: (Surname, Reg ID number). Failure to do so could result in your payment not being identified in the bank account and therefore not being receipted.
  • Registrations are transferable to delegates, within the same rate category, who have not yet registered. The full delegate registration fee amount invoiced must appear in the Congress bank account. Should this not be the case, the delegate will need to pay the difference in via credit card on site before being allowed to participate in the event.
Cancellations of Registrations

On completion of this application, you will be liable for the full amount of the registration fees subject to the cancellation conditions below:

  • All cancellations must be received in writing by the Congress Secretariat – chantell@soafrica.com.
  • Cancellations received on or before 15 January 2026 will receive a full refund, less a USD 25 administration fee.
  • Cancellations received between 16 January 2026 and 28 February 2026 (23:59 GMT +2) will receive a 50% refund.
  • No refunds will be issued for cancellations received after 28 February 2026 (23:59 GMT +2).
  • Any registrations received after 28 February 2026 will not be entitled to any refund or credit, and such person will be liable for the full registration fee as above.

Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in invitro diagnostics. The company strives for scientific excellence in the discovery and development of pharmaceutical and diagnostic solutions, with the aim of enhancing and saving human lives globally. We are a pioneer in personalized healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with real-world data insights.

In recognition of our endeavor to pursue a long-term perspective in all we do, Roche has been name done of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners. Genentech in the United States is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

At Roche, we are dedicated to helping you save patients' lives by providing state-of-the-art blood safety solutions now and in the future. The vision of RBSS is to enhance blood safety through reliable system and assay performance, personalized lab automation, and digital solutions, all supported by continuous portfolio expansion to address key customer needs.

For more information, please visit www.roche.com and the Roche Exhibition Booth for more on our innovative Blood Safety Solutions.

NBI, a South African non-profit pharmaceutical manufacturer, specialises in plasma-derived medicinal products (PDMPs) including clotting factors, immunoglobulins, and albumin solutions. Established in 1995, NBI provides quality, cost-effective therapies aligned with WHO’s Essential medicines list and SAHPRA regulatory standards. Recognising the challenges African countries face in accessing PDMPs due to limited plasma that meets fractionation standards, NBI launched the Plasma from Africa for Africans programme in 2021. Through partnerships with blood establishments advancing through AfSBT’s Step-Wise Accreditation Programme, the initiative strengthens quality systems and builds capacity for plasma collection that meets fractionation standards. By supporting plasma procurement, contract manufacturing, and technical development for blood services across Africa, NBI seeks to make PDMPs affordable and drive regional self-reliance. Through current collaborations, NBI has witnessed countries achieve significant progress in GMP compliance, quality management systems, and investment in infrastructure. At the 2026 AfSBT Congress, NBI looks forward to sharing insights and deepening partnerships to advance PDMP access and self-sufficiency across Africa.

Terumo Blood and Cell Technologies is a medical technology company. Our products, software and services enable customers to collect and prepare blood and cells to help treat challenging diseases and conditions. Our employees around the world believe in the potential of blood and cells to do even more for patients than they do today. This belief inspires our innovation and strengthens our collaboration with customers. 

Terumo Blood and Cell Technologies' customers include blood centers, hospitals, therapeutic apheresis clinics, cell collection and processing organizations, researchers and private medical practices. Our customers are based in over 150 countries across the globe. We have 750+ granted patents, with more than 150 additionally pending. 

We have global headquarters in Lakewood, Colo., U.S.A., along with five regional headquarters, seven manufacturing sites and six innovation and development centers across the globe. Terumo Blood and Cell Technologies is a subsidiary of Terumo Corporation (TSE: 4543), a global leader in medical technology.  

www.terumobct.com

IA global leader in clinical diagnostics, Beckman Coulter Diagnostics has challenged convention to elevate the diagnostic laboratory’s role in improving patient health for more than 80 years. Our mission is to Relentlessly Reimagine Healthcare, One Diagnosis at a Time – and we do this by applying the power of science, technology and the passion and creativity of our teams. Our diagnostic solutions are used in complex clinical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. We exist to deliver smarter, faster diagnostic solutions that move the needle forward from what’s now to what’s next. We do this by accelerating care with an extensive clinical menu, scalable lab automation technologies, insightful clinical informatics, and optimize lab performance services.

Beckman Coulter Diagnostics | Beckman Coulter

Ilex South Africa (PTY) LTD
Ilex South Africa is a trusted partner in the supply and support of advanced diagnostic solutions across Southern Africa. With a core focus on laboratory diagnostics, transfusion medicine, and molecular testing. Ilex South Africa collaborates with internationally recognised manufacturers to provide innovative technologies tailored to the evolving needs of healthcare systems.

As a Platinum Sponsor of the AFSBT Congress 2026, Ilex South Africa reaffirms its commitment to supporting excellence in transfusion services and promoting scientific advancement within the field of blood safety and diagnostics.

Backed by a highly skilled team of professionals, we offer end-to-end support, from consultation and installation to training, maintenance, and after-sales service. Our customer-centric approach ensures optimal performance and reliability of the solutions we deliver, helping laboratories and blood services operate with precision and confidence.

At Ilex South Africa, we believe in building long-term partnerships based on integrity and shared growth by driving innovation, improving patient outcomes, and contributing meaningfully to the healthcare landscape in Africa.

Loading...